AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ZBIO · NASDAQ · Biotechnology

Zenas BioPharma (ZBIO)

Develops obexelimab, a licensed antibody that quiets B-cell activity in immune diseases without depleting the cells.

$32.44

Pre-market−0.65 (−1.98%)

At close$33.09(+3.47%)

Watchlist

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	50	0	0	0	0	5	10	0	0	0	0	1
Cost of revenue	0	20	23	34	34	0	0	43	5	56	0	0
Gross profit	50	−20	−23	−34	−34	5	10	−43	−5	−56	0	1
	14	4	5	6	7	61	47	12	48	182	77	109
Research & development	9	20	23	34	34	49	35	43	34	222	60	63
	5	4	5	6	7	11	12	12	13	16	17	16
Selling & marketing	0	0	0	1	0	0	0	1	0	−1	0	0
General & administrative	5	4	5	5	7	11	12	11	13	17	17	16
Other expenses	0	−20	−23	−34	−34	0	0	−43	0	−56	0	30
Operating income	36	−25	−28	−40	−41	−56	−37	−55	−53	−238	−77	−108
	0	0	0	2	2	3	4	3	1	−2	−4	−4
Interest income	0	0	0	0	0	0	0	0	0	0	3	7
Interest expense	0	0	0	0	0	0	0	0	0	0	7	10
Other non-operating income	0	0	0	−2	−2	−3	−4	−3	−1	−8	−3	−7
Income before tax	36	−24	−28	−38	−39	−52	−34	−52	−51	−240	−81	−111
Income tax expense	0	0	0	0	0	0	0	0	0	0	0	0
Net income from continuing operations	36	−25	−28	−38	−39	−53	−34	−52	−51	−240	−81	−111
Net income	36	−25	−28	−38	−39	−53	−34	−52	−51	−240	−81	−111
EPS, basic	$0.21	−$0.64	−$0.73	−$0.99	−$0.92	−$1.26	−$0.80	−$1.25	−$1.22	−$5.17	−$1.46	−$1.77
EPS, diluted	$0.21	−$0.64	−$0.73	−$0.99	−$0.92	−$1.26	−$0.80	−$1.25	−$1.22	−$5.17	−$1.46	−$1.77
Weighted average shares, basic	42	38	38	38	42	42	42	42	42	46	56	63
Weighted average shares, diluted	42	38	38	38	42	42	42	42	42	46	56	63
EBITDA	36	−24	−28	−38	−39	−52	−34	−52	−51	−230	−74	−101
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	36	−24	−28	−38	−39	−52	−34	−52	−51	−230	−74	−101